HIV/AIDS Therapy

Aptivus demonstrates durable response through nearly 2 years

Published in Immunotherapy Weekly, November 8th, 2006

New data from a 96-week combined analysis of RESIST-1 and RESIST-2 show that Aptivus (tipranavir) provides a superior and durable treatment response in highly treatment-experienced patients when used with ritonavir (Aptivus/r), as part of combination antiretroviral therapy.

These data were presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, California.

"Treatment-experienced patients continue to respond to Aptivus after 2 years of therapy in the RESIST study," said Margaret Johnson, MD, clinical director, HIV/AIDS services, Royal Free Hospital, London, England. "As HIV-positive patients...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2006-11-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry